TGFB1 and ovarian carcinoma: Vactosertib has shown signals of activity in combination with pembrolizumab in microsatellite-stable colorectal cancer and favorable safety in hematologic malignancy when paired with an immunomodulatory backbone, motivating disease-adapted trials in ovarian cancer cohorts molecularly enriched for TGF-β–conditioned exclusion.